Laura Kleiman is the Founder and CEO of Reboot Rx, the tech nonprofit startup dedicated to saving the lives of cancer patients with repurposed generic drugs. Reboot Rx is building AI technology to rapidly review the extraordinary amount of data on generics and identify the most promising drugs for repurposing. By bringing together stakeholders, Reboot Rx is developing new models for funding clinical trials and for incorporating generics into the standard of care for cancer patients.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.
Repurposing existing drugs, especially off-patent generics, is the fastest way to develop new cancer treatments.